Examination of bone mineral density in patients with varied liver diseases - a cross-sectional study
World Journal of Hepatology · 27.08.2026 · 18 (8)
DOI: 10.4254/wjh.120697 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift World Journal of Hepatology, online erschienen am 27.08.2026. Verfasst von Oliver Rohland und 10 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Chronic liver disease is associated with profound alterations in bone metabolism, predisposing patients to secondary osteoporosis and fragility fractures - a condition commonly termed hepatic osteodystrophy. The pathogenesis of bone loss in chronic liver disease is multifactorial, involving increased osteoclastic activity, impaired osteoblast function, chronic inflammation, malnutrition, and deficiencies of vitamin D and K. Among these, cholestatic liver diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are particularly prone to severe bone loss, whereas viral hepatitis and autoimmune hepatitis (AIH) may contribute through inflammatory and steroid-mediated mechanisms. Despite this, comparative data on bone mineral density (BMD) across different etiologies of end-stage liver disease remain limited, particularly in patients awaiting liver transplantation. AIM To compare BMD and bone turnover markers among patients with different etiologies of end-stage liver disease listed for liver transplantation. METHODS This retrospective, cross-sectional study included 82 patients with end-stage liver disease: AIH, hepatitis C virus infection, PBC, PSC, and polycystic liver disease. Areal BMD at the lumbar spine and femoral neck was measured using dual-energy X-ray absorptiometry. Standard hepatic parameters (bilirubin, international normalized ratio, creatinine, albumin), and bone turnover and micronutrient markers (25-hydroxyvitamin D, parathyroid hormone, osteocalcin, phosphate, calcium, magnesium, ferritin, zinc, and copper.) were analyzed from clinical laboratory data. The Model of End-stage Liver Disease-score and Child-Pugh scores were analyzed. Data on current or prior use of bisphosphonates and glucocorticoids were extracted from patient records. RESULTS All liver disease groups showed significantly reduced lumbar spine BMD compared to controls (P < 0.01), with the lowest lumbar spine T-scores in PBC (-2.5) and PSC (-2.1). Femoral BMD was less affected but still reduced in several groups. Elevated osteocalcin and parathormone levels were most pronounced in patients with hepatic cysts. AIH patients exhibited less severe bone loss, despite glucocorticoid exposure in some cases. CONCLUSION Reduced BMD is prevalent across hepatic disease entities in liver transplant candidates, particularly in cholestatic and cystic liver disease. Early screening and targeted bone-protective strategies are essential to mitigate fracture risk in this population.
Zitieren
APA
Rohland, O., Schwarzer, L., Schwenk, L., Pollmann, N., Deeb, A. A., Settmacher, U., Rauchfuss, F., Dondorf, F., Amrein, K., Kocijan, R., & Ardelt, M. (2026). Examination of bone mineral density in patients with varied liver diseases - a cross-sectional study. World Journal of Hepatology, 18(8). https://doi.org/10.4254/wjh.120697
Vancouver
Rohland O, Schwarzer L, Schwenk L, Pollmann N, Deeb AA, Settmacher U, et al. Examination of bone mineral density in patients with varied liver diseases - a cross-sectional study. World Journal of Hepatology. 2026;18(8). doi:10.4254/wjh.120697
BibTeX
@article{Rohland2026,
author = {Rohland, Oliver and Schwarzer, Lysann and Schwenk, Laura and Pollmann, Nicola and Deeb, Aladdin Ali and Settmacher, Utz and Rauchfuss, Falk and Dondorf, Felix and Amrein, Karin and Kocijan, Roland and Ardelt, Michael},
title = {Examination of bone mineral density in patients with varied liver diseases - a cross-sectional study},
journal = {World Journal of Hepatology},
year = {2026},
volume = {18},
number = {8},
doi = {10.4254/wjh.120697}
}
EUVIMED